Cited by 84Adrenal and Paraganglionic TumorsRenal cell carcinoma treatmentAdrenal Hormones and Disorders

Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade

Miller, Barbra S., Gauger, Paul G., Hammer, Gary D., Giordano, Thomas J., Doherty, Gerard M.·2010·Langenbeck s Archives of Surgery

Abstract

Purpose Various staging systems for adrenocortical carcinoma (ACC) have been proposed. We hypothesized that incorporating tumor grade into the current European Network for the Study of Adrenal Tumors (ENSAT) staging system would improve the ability to more accurately predict time to recurrence and death.Methods A retrospective review of patients included in the University of Michigan ACC database from 2005 to 2009 was done; and stage, tumor grade, time to recurrence, and death were recorded and analyzed using the Cox regression and Kaplan-Meier survival curves.Results Ninety one patients had complete information for inclusion. The median follow-up was 24 months while the median time to recurrence was 4.1 months. There were 28 deaths; overall, tumor grade showed a significant difference in time to tumor recurrence (p = 0.011) and time to death (p = 0.004). Time to death among stage 2 patients separated into those with high- and low-grade tumors reached statistical significance (p = 0.05), and notable but not statistically significant differences were identified in all stages. Based on tumor grade and survival curves, modifications to the current ENSAT staging system were made.Conclusion Tumor grade plays a significant role in the outcome of patients with ACC. High-grade tumors are associated with shorter disease-free intervals and shorter overall survival. The proposed modification of the ENSAT staging system allows for incorporation of tumor grade when predicting overall survival.

Integrity signals

Registry

Crossref · 10.1007/s00423-010-0698-y

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • High tumor grade (>20 mitoses per HPF) is an unfavorable prognostic indicator.

    “High tumor grade (>20 mitoses per HPF) is also an unfavorable prognostic indicator (245).”

    From Adrenocortical carcinoma (2014) · cites this paper as [245]

  • Tumor grade correlates with survival.

    “Tumor grade influences the decision for reoperation because it correlates with survival (243, 245).”

    From Adrenocortical carcinoma (2014) · cites this paper as [245]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Miller, B. S., Gauger, P. G., Hammer, G. D., Giordano, T. J., & Doherty, G. M.
Affiliations
University of Michigan (US)
Corresponding author
Miller, Barbra S.
Venue
Langenbeck s Archives of Surgery
Published
2010-08-09
Volume
395
Issue
7
Pages
955-961
ISSN
  • 0023-8236 (ISSN-L)
  • 1435-2443
  • 1435-2451
OpenAlex
W2044712887
Cited by
84
References
27
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 8 · 2020: 8 · 2019: 7 · 2018: 6 · 2017: 1 · 2016: 5 · 2015: 9 · 2014: 10 · 2013: 6 · 2012: 1
FWCI
3.71
Type
journal article
Language
en
Open access
closed
Locations
  • Langenbeck s Archives of Surgery (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
adrenocortical carcinoma, tumor grade, tumor staging, time to recurrence, overall survival, disease-free interval, prognostic factors
MeSH terms
Adolescent, Adrenal Cortex Neoplasms, Adrenalectomy, Adult, Aged, Biopsy, Needle, Female, Follow-Up Studies, Forecasting, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Retrospective Studies, Sensitivity and Specificity, Time Factors, Cohort Studies, Proportional Hazards Models, Survival Analysis, Treatment Outcome, Adrenocortical Carcinoma, Risk Assessment, Statistics, Nonparametric, Kaplan-Meier Estimate, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review